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Abstract
Background: In select patients with heart failure, cardiac resynchronization therapy (CRT) is the 
most common complementary treatment besides medical treatment. We aimed to assess the association 
between post CRT-implant changes in cardiovascular medication and cardiovascular mortality and 
heart failure hospitalization. 
Methods: 211 patients on optimal medical therapy eligible for CRT were retrospectively included in 
this study (72 ± 7 years, 80% male, 66% left bundle branch block, 48% dilated cardiomyopathy and 
investigated at baseline and after 6 months. Follow-up with medication, biochemical markers and 
echocardiography was performed and 3-year mortality data was collected. 
Results: At 6 months post-implant the cohort was divided into two groups; 157 patients had low 
dosage furosemide treatment (up to 40 mg) and 54 patients were treated with high dosage (> 40 mg).  
A composite endpoint of heart failure hospitalization and all-cause mortality was evaluated at  
30 months (881 ± 267 days) after the 6-month visit. In multivariate Cox regression analysis, pa-
tients in the high dose diuretics group had a higher risk of the primary endpoint (HR 1.9 [1.1–3.4],  
p = 0.033), but treatment with high dose diuretics was not associated with improved clinical symptoms  
(r = 0.031, p = 0.64). 
Conclusions: High dosage of loop-diuretics was associated with worse medium-term clinical outcome 
in CRT treated patients. It is unclear whether there is a direct causality between these associations, or 
if higher prescribed dosage of loop-diuretics is just a marker of more severe disease. Higher dose loop 
diuretics do not necessarily improve the symptoms and may be harmful to the patient. Prospective trials 
are warranted to further elucidate these findings. (Cardiol J 2017; 24, 4: 374–384)
Key words: cardiac resynchronization therapy, heart failure, dilated cardiomyopathy, 
ischaemic heart failure, medical therapy, loop diuretics 
Introduction
Heart failure (HF) is a common cause of death 
in developed countries [1]. In the last decade cardiac 
resynchronization therapy (CRT) has emerged as 
a complement to medical therapy in patients with wide 
QRS and impaired left ventricular ejection fraction 
[2, 3]. Large randomized trials have demonstrated the 
advantage of CRT, however 30–40% of the patients 
have no perceived benefit; so called non-responders. 
The reason for non-response seems to be multifacto-
rial, and data from different trials suggest that patient 
selection, electrode placement, and optimization of 
therapy at follow-up all play a role [4–10]. Medical 
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therapy with beta-blockers, angiotensin converting 
enzyme inhibitors (ACEI) or angiotensin-receptor 
blockers (ARBs) and aldosterone antagonists [11–13] 
are all important in HF treatment with proven long 
term benefits in terms of morbidity and mortality 
[14]. Aldosterone receptor inhibitors are also an 
important part of the medical therapy; however, 
they are less-tolerated mainly due to the elevated 
serum potassium level [15]. Angiotensin receptor 
blocker with neprilysin inhibitor (ARNI), as a new 
medical treatment is on the horizon for HF popula-
tion, however the long-term effect of the treatment 
is unknown, and there are no data about this therapy 
in the CRT population [16]. The potential risks and 
benefits by changing the medication for CRT-treated 
patients are less documented, and it is still unclear to 
what extent changes in medical therapy can influence 
clinical outcome in this subpopulation. Data regard-
ing medication changes and prognostic outcome is 
lacking for CRT-treated patients outside the clinical 
trial setting, but could add knowledge concerning 
clinical prognosis for these patients. A few studies 
have suggested that loop diuretic therapy is associ-
ated with higher mortality in non-CRT HF patients 
[17], but only one prospective study has evaluated 
this in a HF population with mild symptoms after 
CRT implantation [18]. The aim in this study was 
to assess the association between the efficacy and 
clinical outcome of CRT in relation to concurrent use 
of HF medications, more specifically loop-diuretic 
therapy due to its ambiguous effect on morbidity 
and mortality.
Methods
Consecutive patients receiving CRT in 
a tertiary Swedish centre between 2011 and 2014 
were included retrospectively. All patients had 
indications for CRT according to the European 
Society of Cardiology (ESC) recommendations [19, 
20]. Patients were on HF therapy with the highest 
tolerable dosage of beta-blocker and ACEI/ARB 
prior to implantation. Mortality data up to 4 years 
was extracted from the Swedish National Cause 
of Death Registry. Clinical data was evaluated at 
6-month post-implant, and retrospectively collect-
ed for baseline parameters. Prior to implantation, 
all patients had an assessment of their preopera-
tive functional clinical status. Subjective clinical 
improvement and New York Heart Association 
(NYHA) classification was assessed by the study 
physician 6 months after the implantation. A subset 
of patients had available preoperative and follow up 
data from standardized HF questionnaires (Minne-
sota living with heart failure questionnaires [ML-
HFQ]) and quality of life questionnaires (EQ5D). 
Medical information, 12-lead electrocardiogram 
(ECG), laboratory examinations and a standardized 
echocardiography protocol was extracted from the 
local electronic medical record system. Written in-
formed consent was collected before the enrolment 
and the local ethics committee approved the study. 
Medication
Information about beta-blockers, ACEI, ARBs, 
statins, diuretics, aldosterone inhibitors, thrombo-
cyte aggregation inhibitors, oral anticoagulation 
drugs were collected at baseline and 6 months. 
Changes in dosages and between substances were 
recorded, which was initiated under the supervi-
sion of the treating physician. Optimal medical 
therapy was considered as the highest tolerable 
dosage of beta-blocker and ACEI or ARB as crite-
ria for CRT treatment. Loop diuretic therapy was 
indicated according to the ESC recommendation 
[14] and the decision making about changes in 
medication over time was at the discretion of the 
treating physicians.
Heart failure symptom evaluation
Minnesota living with heart failure ques-
tionnaires (MLHFQ) [21–23] and standardized 
instrument for use as a measure of health out-
come (EQ5D) [24] formularies and Self Rated 
Health (EQ VAS) questionnaires were filled in 
and collected at baseline and 6 months after the 
implantation. NYHA classification at baseline and 
at the 6 month visit was evaluated and the enrolled 
study subjects were directly asked about subjec-
tive improvement.
Echocardiography
Preoperative and at 6-month echocardiography 
was performed in all patients. Off-line analysis 
was performed with Echopac BT12 software 
(Echopac BT12, GE Medical, Hortens, Norway). 
Left ventricular (LV) volumes and ejection frac-
tion (EF) were measured with Simpson’s biplane 
method [25]. Left ventricular end-diastolic volume 
(LVEDV) and left ventricular end-systolic volume 
(LVESV) were measured, and LVESV index were 
calculated (LVESVi) [26–30]. Mitral regurgitation 
(MR) was graded 0–3 according to current guide-
lines [31]. Septal to posterior wall motion delay 
was measured as the shortest interval between 
the maximal displacement of the septum and the 
posterior wall in milliseconds using 2-dimensional 
papillary muscle level short axis view [32].
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Definition of positive response to CRT
At least 15% reduction or more of the LVESV 
[33] was considered as reverse remodeling and 
positive echocardiographic response to the therapy. 
Positive clinical response was defined as ≥ l NYHA 
class improvement.
Device implantation and follow up
Device implantation was performed using left 
subclavian vascular access. A lateral or posterolateral 
coronary sinus branch was targeted for the LV lead 
positioning. The majority of patients (n = 128) re-
ceived a St. Jude Quickopt®-algorithm capable device 
using the algorithm recommended settings. The rest 
of the patients (n = 83) received a Medtronic device, 
with fixed atrio-ventricular delays of 120/150 ms and 
simultaneous VV-times. 
End point of the study
The primary endpoint of the present study 
was death, and secondary endpoint was death or 
hospitalization for HF. The diagnosis of HF was 
based either on the medical records or on the record 
linkage with the national Swedish Patient Registry, if 
the primary cause of hospitalization was listed as HF. 
Statistical analyses
SPSS statistical software was used for data analy-
sis (IBM, SPSS ver.: 21. 2012). Continuous variables 
are expressed as means (± standard deviation [SD]), 
categorical variables are presented as frequencies and 
percentages. For non-normally distributed continuous 
variables the median value with interquartile range 
(IQR) is presented. Differences between groups were 
assessed using paired and unpaired Student t-tests 
for continuous variables, Mann-Whitney U test for 
variables with non-Gaussian distribution, and the c2 
test for categorical variables, or the Fisher’s exact test 
for unordered categorical variables as appropriate. For 
survival analysis Kaplan-Meier method with log-rank 
test were used to analyze the cumulative events. Cox 
regression analysis was used to determine the Hazard 
ratio (HR) with 95% confidence interval (CI) for clinical 
endpoints. The proportional hazards assumption was 
tested by log minus log curves and was met. Variables 
with a p < 0.10 were then entered into a multivariate 
model. Pearson’s r test was performed to calculate the 
correlation coefficient. A two-sided p-value < 0.05 was 
considered statistically significant. 
Results
Clinical characteristics of the overall study 
population
The group of 398 patients were invited and 211 
of these were enrolled. The inclusion process is 
summarized in Figure 1. The included patients were 
divided in two subgroups, depending the dosage of 
Figure 1. The flow chart demonstrates the inclusion process and the response to the cardiac resynchronization 
therapy. The different type of response are also represented on the figure.
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the loop diuretics at 6-month follow up. Based on 
previous studies, the cut-off value between low and 
high dosage of furosemide was set at 40 mg [17]. In 
the low dose group (Group I) the patients had loop 
diuretic treatment with furosemide up to 40 mg 
(n = 157). Patients with > 40 mg furosemide were 
classified as high dose group (Group II, n = 54). The 
baseline characteristics of the whole cohort and the 
two subgroups are presented in Table 1.
The medical therapy initially included beta-
-blocker in 89%, ACEI/ARB in 96% and aldosterone 
blockade in 58% of the patients. At 6 months, 87% 
were on a beta-blocker, 92% on an ACEI/ARB and 
53% were on aldosterone therapy. Table 2 shows 
Table 1. Study population characteristics. The first column represents the whole study population. The 
second and third columns show the two groups with low and high dose diuretics. The last column 
shows the p-value for difference between the subgroups.
Overall Group I (n = 157) Group II (n = 54) P 
Age [years] ± SD 71.6 ± 7 71.5 ± 8 71.6 ± 8 0.96
QRS duration [ms]        164%%   163%   166% 0.29
Male   80%   80%   85% 0.37
Ischemic cardiomyopathy   52%   47%   68% 0.01
Hypertension   59%   55%   74% 0.02
Presence of diabetes   23%   19%   35% 0.02
Renal failure   13%   11%   18% 0.16
History of AF   50%   48%   61% 0.12
History of CABG   29%   26%   41% 0.06
History of MI 52%   46%   68% 0.01
CRT-P   24%   24%   24% 1
LBBB/Non LBBB/PM 66%/18%/16% 67%/19%/14% 57%/20%/22% 0.31
Echo responder   62%   59%   65% 0.47
Clinical responder   58%   61%   54% 0.42
AF — atrial fibrillation; CABG — coronary artery bypass surgery; CRT-P — cardiac resynchronization therapy without defibrillator function; 
ICMP — ischemic cardiomyopathy; LBBB — left bundle branch block; MI — myocardial injury/infarction; PM — pacemaker rhythm;  
SD — standard deviation
Table 2. Medical therapy for the two groups at baseline and at 6 months (%). The last column shows 
the p-value for difference between the subgroups.
Medication (in %) Group I (n = 157) Group II (n = 54) P 
Baseline
Beta-blocker 87 92 0.33
ACEI/ARB 96 93 0.28
Digoxin 12 13 0.76
Statin therapy 60 70 0.56
Aldosterone antagonist 49 65 0.09
Thiazide diuretics 4 5 0.65
6-month follow up
Beta-blocker 86 92 0.41
ACEI/ARB 89 89 0.29
Digoxin 11 12 0.26
Statin therapy 56 72 0.40
Aldosterone antagonist 45 76 0.01
Thiazide diuretics 4 5 0.62
ACEI — angiotensin converting enzyme inhibitor; ARB — angiotensin receptor blocker
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information about the HF therapy, comparing 
baseline and 6-month visit data: At baseline, 68% 
of the patients were on loop diuretic therapy, and at 
6 months the corresponding percentage was 62% 
on loop diuretic therapy (p = 0.006). In Group I the 
percentage of patients with loop diuretic therapy 
decreased significantly (58% preoperatively vs. 
49% at 6-month follow-up, p = 0.002), however 
similar changes were not observed in Group II 
(96% at baseline vs. 100% at 6-month follow-up, 
p = 0.32). The mean furosemide dose in Group I 
pre-implant was 42 ± 17 mg, which was decreased 
to 36 ± 7 mg (p = 0.01) at 6 months. In Group 
II the initial mean dosage of the furosemide was 
100 ± 65 mg at baseline, and it increased to 115 ± 
± 85 mg at 6 months (p = 0.11).
Biochemical markers
At baseline, slightly elevated creatinine in 
Group II was observed compared with Group I 
(124 ± 49 µmol/L vs. 103 ± 60 µmol/L, p = 0.09) 
and at 6 months, the difference became significant 
(126 ± 58 µmol/L vs. 108 ± 50 µmol/L, p = 0.03). 
However, the change of the creatinine level from 
baseline to 6-months within the respective groups 
did not differ significantly (p = 0.16, p = 0.44). 
The N-terminal pro B-type natriuretic peptide 
(NT-proBNP) in Group II improved significantly 
(from median 3848 ng/L [IQR: 3575] to 2039 ng/L 
[IQR: 2311], p = 0.03) as well as in Group I (from 
3695 ng/L [3581] to 2740 ng/L [2427], p = 0.05). 
However, no significant difference at baseline 
(p = 0.73) or at follow-up (p = 0.69) was found 
in NT-proBNP levels, between the two groups. 
Association between cardiovascular  
medication and clinical improvement 
Self-assessed quality of life pre-implant (1–100 
scale) was similar in the two groups (57 ± 21 
vs. 59 ± 20, p = 0.78). However, at the 6-month 
follow-up, patients in Group I had a better overall 
subjective health assessment compared to patients 
in Group II (69 ± 18 vs. 62 ± 20, p = 0.03). The 
mean NYHA classification at baseline was similar 
in both subgroups. Sixty-six percent of the patients 
showed improvement in NYHA class and the 
improvement in both groups were similar during 
the 6-month follow-up, as presented in Table 3 
(p < 0.01 in both group). Improvement of the 
NYHA class was neither correlated to aldosterone 
antagonist therapy (r = 0.08, p = 0.25), nor to loop 
diuretic treatment (r = 0.03, p = 0.64) or beta-
blocker therapy (r = 0.001, p = 0.99) at 6-months. 
No correlation was observed between baseline 
beta-blocker (r = 0.03, p = 0.62), aldosterone 
inhibitor (r = 0.03, p = 0.61), or loop diuretic 
(r = 0.04, p = 0.54) therapy and clinical improve-
ment. In contrast, clinical improvement did show 
a correlation with baseline ACEI/ARB therapy 
(r = 0.17, p = 0.01) and 6 month ACEI/ARB 
therapy (r = 0.15, p = 0.03).
Association between cardiovascular  
medication and reverse remodeling
Sixty-one percent of the patients (n = 128) 
showed more than 15% reduction in the LVESV 
(64% in Group I, 56% in Group II, p = 0.37). The 
overall mean LVEF improved in the whole popu-
lation (from 27 ± 8% to 35 ± 13% p = 0.001). 
Correlations between reverse remodeling and HF 
medications were tested. Reduction in LVESV 
showed a positive trend in correlation with base-
line beta-blocker (r = 0.117, p = 0.049) and ACEI 
(r = 0.283, p = 0.066) therapy. However, diuretic 
therapy with furosemide (r = 0.042, p = 0.58) or 
aldosterone inhibitors (r = 0.047, p = 0.54) was not 
associated with reverse remodeling. Improvement 
of the LVEF showed no correlation with the loop di-
uretic therapy (r = 1, p = 0.38) or with aldosterone 
antagonist treatment (r = 0.08, p = 0.3). The mitral 
regurgitation improved during this 6 month follow 
up (p < 0.01). Initially 28 patients had grade II and 
only 2 patients had grade III mitral regurgitation. 
At 6 month control the mitral regurgitation had 
improved, only 6 patients had grade II regurgita-
tion, and only 1 patient had grade III regurgitation 
due to mitral prolapse. The improvement of the 
regurgitation was not correlated with the dose of 
the diuretic therapy (r = 0.02, p = 0.85).
Association between cardiovascular  
medication and clinical endpoints
During the whole follow up period (826 ± 331 
days) 26 deaths and 27 hospitalizations for HF were 
observed. 14 patients were hospitalized due to HF 
and 2 patients died before the 6-month follow up 
visit in sudden cardiac death despite CRT-D, and 
these events were excluded from the outcome 
analyses. During the remainder of the follow-
up, 13 deaths occurred in Group I and 11 deaths 
were observed in Group II. The effect on clinical 
outcome of medical therapy using ACEI/ARBs, 
beta-blockers or aldosterone antagonists was ex-
amined by univariate Cox regression analysis. In 
the univariate Cox regression analysis, high dose 
loop diuretic therapy was associated with a HR of 
1.94 (95% CI 1.11–3.376). Accordingly, in Kaplan-
-Meier analysis a significant difference was found 
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Table 3. Biochemical marker levels, clinical symptoms and echocardiographic parameters for the two 
groups at baseline and at 6 months. The last column shows the p-value for difference between the 
subgroups. The D-values show the mean (± standard deviation) difference between the baseline and 
6-month values of each parameter. 
Variable Group I (n = 157) Group II (n = 54) P
Biochemistry
Baseline creatinine [mmol/L] 103 ± 89 124 ± 49 0.09
6-month creatinine [mmol/L] 108 ± 50 126 ± 58 0.03
Baseline hemoglobin [g/L] 136 ± 14 132 ± 16 0.12
6-month hemoglobin [g/L] 137 ± 13 135 ± 16 0.34
Baseline NT-proBNP [ng/L] 3615 ± 5617 3950 ± 5384 0.73
6-month NT-proBNP [ng/L] 2646 ± 5295 2314 ± 2950 0.69
Clinical markers
Baseline MLWHF 40 ± 20 44 ± 25 0.55
6-month MLWHF 27 ± 20 39 ± 24 0.001
Baseline EQ5D 5.7 ± 3.7 5.4 ± 3.8 0.76
6-month EQ5D 6.1 ± 2.5 6.2 ± 3 0.75
Baseline EQ-VAS 57 ± 21 59 ± 20 0.78
6-month EQ-VAS 69 ± 18 62 ± 20 0.03
NYHA baseline 2.4 ± 0.8 2.4 ± 0.8 0.95
6-month NYHA 1.7 ± 0.6 1.7 ± 0.7 0.76
Echocardiography
Baseline LVESV BP [mL] 141 ± 53 173 ± 81 0.03
Baseline LVEDV BP [mL] 196 ± 65 228 ± 92 0.02
Baseline LVEF BP [mL] 27 ± 8 25 ± 8 0.14
6-month LVESV BP [mL] 112 ± 52 141 ± 85 0.03
6-month LVEDV BP [mL] 164 ± 60 205 ± 97 0.01
6-month LVEF BP [mL] 36 ± 15 33 ± 8 0.23
Baseline mitral regurgitation 1 ± 0.57 1.1 ± 0.51 0.80
6-month mitral regurgitation 0.81 ± 0.51 0.86 ± 0.46 0.62
Difference between the baseline and 6-month values
D LVESV BP [mL] 32 ± 40 32 ± 50 0.97
D LVEDV BP [mL] 32 ± 51 25 ± 58 0.40
D LVEF BP [mL] 8 ± 15 7 ± 9 0.48
BP — biplane view; LVEF — left ventricular ejection fraction; LVEDV — left ventricular end diastolic volume; LVESV — left ventricular end  
systolic volume; MLFHQ — Minnesota living with heart failure questionaires; NT-proBNP — N-terminal pro B-type natriuretic peptide
between the two groups (p = 0.03; Fig. 2). Absence 
of beta-blocker or aldosterone antagonist therapy 
showed no influence on the primary endpoint us-
ing univariate analysis, but ACEI/ARB therapy 
significantly reduced risk (HR = 0.35, 95% CI 
0.123–0.988, p = 0.04). In the multivariate Cox re-
gression model, high dose diuretic therapy adjusted 
for age, sex, aetiology, renal disease, showed a HR 
of 2.1 (95% CI 1.0–4.2, p = 0.04) for the primary 
endpoint. None of the other variables, such as 
ischemic etiology of HF (p = 0.82, HR = 0.93, 95% 
CI 0.49–1.78), renal disease (p = 0.57, HR = 1.27, 
95% CI 0.553–2.91), or echocardiographic response 
(p = 0.96, HR = 0.98, 95% CI 0.57–1.7) showed 
independent predictive value for clinical outcome.
Association between diuretic therapy and 
cardiac device type was noted. Fifty patients re-
ceived CRT without defibrillator function (CRT-P) 
device and the majority of the population (n = 161) 
had CRT with defibrillator function (CRT-D) im-
planted. The distribution of CRT-D therapy was 
similar in Group I and Group II (75% vs. 74%, 
p = 0.9). As expected, the CRT-P patients were old-
er (76 ± 9 vs. 70 ± 9 years, p = 0.001), but had sim-
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ilar NYHA class (2.6 ± 0.5 vs. 2.5 ± 0.6, p = 0.07) 
at baseline. The NYHA class improvement was 
slightly better in the CRT-D treated patients at 
6 months (1.8 ± 0.6 vs. 1.9 ± 0.6, p = 0.055). In 
patients with CRT-D devices, no prognostic differ-
ence was found when stratifying for diuretic thera-
py dosage (Group I: n = 120 vs. Group II: n = 41, 
p = 0.15) regarding composite clinical end points 
(Fig. 3A), but in patients with CRT-P devices low 
dose diuretic therapy (Group I: n = 37) patients 
had a better survival compared with higher dosages 
(Group II: n = 13), p = 0.02 (Fig. 3B). 
Discussion
Our main finding in this observational study 
suggests that higher dosage loop diuretic therapy 
at follow up is independently associated with 
increased risk for medium term death or HF 
hospitalization. It is unclear whether the diuretic 
therapy itself creates an unfavourable circum-
stance or the lack of positive improvement leads 
to higher dosage treatment for symptom relief. 
Patients who required higher diuretic treatment 
were older and had higher prevalence of hyper-
tension, ischemic heart disease and diabetes 
mellitus. This finding also supports, that more 
ill patients often require more diuretic therapy, 
mainly due to dyspnoea or fluid retention.
The survival and clinical benefit of the CRT 
is well studied, however the risk of unfavourable 
events with loop diuretics is less studied in this 
Figure 3. A. Kaplan-Meier demonstrates the event free survival in cardiac resynchronization therapy with defibrilla-
tor function (CRT-D) treated patients with low (Group I) and high (Group II) dose diuretics, respectively. The curve is 
a landmark analysis reset at the 6 month follow-up visit. The difference between the two groups is not significant, 
p = 0.15; B. Kaplan Meier curve demonstrates the event free survival in cardiac resynchronisation therapy without de-
fibrillator function (CRT-P) treated patients with low (Group I) and high (Group II) dose diuretics. The curve is a landmark 
analysis reset at the six-month follow-up visit. Patients with high loop diuretic therapy has worse outcome, p = 0.02.
Figure 2. Kaplan-Meier curve is showing the event free 
survival in patients with low (Group I) and high (Group II) 
dose diuretics respectively. The curve is a landmark 
analysis reset at the 6-month follow-up visit.
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population. The major finding of this study sug-
gests that the increased diuretic therapy with 
high dose loop diuretics may be associated with 
a negative influence on survival and risk of HF 
hospitalization. The risk for hospitalization/death 
were more pronounced in the group of CRT-P 
treated patients, who represented a slightly older 
population with more comorbidity, compared to 
the CRT-D treated patients. No positive correla-
tion between loop diuretic dosages and clinical 
improvement or reverse remodeling was found, 
regardless of implanted device type.
In “real life”, treating the failing heart might 
differ in some details compared to what is seen 
in the large clinical trials, even though the long-
-term benefits of medical and CRT therapy in 
terms of mortality have been well established by 
the prospective randomized trials. Depending on 
the local routines, experiences and possibilities, 
the optimal medical therapy including dosages 
may differ.
Routinely, many patients are started on loop 
diuretics at a time with decompensated HF be-
fore the CRT implantation, but over time — and 
especially post-CRT implant — many of them 
improve their symptoms including mitral regur-
gitation [34–37], but nevertheless continue on 
the same dose of diuretics and are thus treated 
with a higher dose than necessary. On the other 
hand, HF therapy is often made complicated by 
patient specific factors such as low blood pres-
sure, renal dysfunction, and not least by patient 
preferences and compliance. 
Loop diuretic therapy is one of the most 
commonly used complementary medications 
for symptom relief and for reducing fluid re-
tention, but long-term data suggests potential 
harmful effect in higher dosages [17, 38]. Early 
experimental studies have suggested that in 
HF without congestion, furosemide therapy can 
activate the renin-angiotensin system and thus 
can influence the HF negatively [39]. An Italian 
study with 813 ambulatory patients with mild to 
moderate HF, and found that more than 50 mg 
furosemide daily increased the 3-year mortal-
ity [17]. A recent prospective study with 244 
stable non-CRT treated HF patients also found 
that higher furosemide dose was associated with 
increased morbidity and mortality, and only 40 mg 
furosemide daily on top of the standard HF 
therapy resulted in 66% increased risk of adverse 
event [38]. That population was younger and had 
less comorbidity compared to this present one, 
but the medical therapy was comparable in both 
studies. Similar to findings herein, the high dose 
diuretic therapy also had slightly more comor-
bidity, higher frequency of renal impairment and 
more often had ischemic cardiomyopathy and also 
presented worse outcomes when compared with 
low dose treatment. Furthermore, Penn et al. [18] 
used the MADIT-CRT data for investigation and 
also found that in mild HF patients after CRT im-
plantation, higher diuretic usage was correlated 
with increased risk of death and hospitalization 
[18]. However up to date there is no data to sup-
port a specific cut-off level for the potentially 
harmful effects of loop diuretic therapy, and the 
lack of reduction of the loop diuretic therapy 
itself can perhaps be considered a potential risk. 
Thus, in harmony with other trials, this 
data also suggests that high dose furosemide 
therapy may be non-beneficial in the long term 
[17]. Independently from clinical improvement, 
renal function or reverse remodeling, higher 
dose diuretic therapy with furosemide appears to 
be unfavourable in terms of long term survival. 
High dose loop diuretic therapy was associated 
with larger LVESV and LVEDV, but reverse 
remodeling was similar in both groups and no 
significant difference in this regard was found 
between them. The negative influence of the loop 
diuretic therapy seems to be more prominent in 
CRT-P recipients who represent an older popula-
tion with relatively more comorbidity within the 
CRT group. Loop diuretics may increase the risk 
of hypokalemia induced malignant arrhythmias 
and sudden cardiac death, which in theory may 
explain the difference in outcome for CRT-P 
treated patients compared to CRT-D. However, of 
the 26 deaths only two were classified as sudden 
cardiac death, and these patients both received 
a CRT-D device. 
Together with previously published results, 
the present data suggest that a high awareness 
is warranted regarding cardiovascular medication 
changes for CRT-treated patients. CRT has the 
potential to induce substantial changes in the 
cardiac function [40], which in turn may influence 
blood pressure, renal function and fluid status of 
the patient. It is imperative to make a renewed 
assessment of fluid status and loop diuretic need, 
after the expected (potential) remodelling effect 
of CRT has taken place, in order to re-evaluate 
the indication and required dosages for the treat-
ment. For patients where no diuretic reduction is 
possible, or where an increased dosage of diuretic 
is required, special attention is warranted. These 
patients are likely to be at increased risk of HF 
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related morbidity and mortality, and every effort 
should therefore be made for individual optimiza-
tion of the CRT-settings and other cardiovascular 
medications for these patients.
Limitations of the study
We acknowledge that there are several limi-
tations to this study. It is a single-centre retro-
spective study, based on registry data. From the 
invited 398 patients only 211 participated in this 
trial therefore selection bias cannot be ruled out. 
All efforts were made to reach the most optimal 
biventricular pacing, however full data on this was 
not available for the current analyses. Data about 
the medication was collected from the local medical 
database and from the participants but no verifica-
tion was available for compliance on individual 
level. Medication changes during the study were 
at the discretion of the patient’s treating physician 
and the study group had no influence on these 
changes. Clinical endpoints were collected from 
the validated Swedish national death and hospitali-
zation registries, which ensures a high accuracy, 
even though no individual scrutiny of the electronic 
medical records was possible regarding mortality 
cause. The reduction of the NT-proBNP — which is 
an important HF marker — can also be secondary 
to the improvement of the fluid balance in some 
patients, this cannot be ruled out. However, all of 
the study subjects were on optimal medical therapy 
before the CRT implantation with stable HF status.
Conclusions
In this observational study, higher dosages 
of loop diuretic therapy were associated with 
worse medium-term clinical outcome in CRT 
treated patients. However, higher doses of loop 
diuretic therapy showed no influence on echo-
cardiographic remodeling response, or on clinical 
improvement. It is unclear whether there is 
a direct causality between these associations, or 
if higher prescribed dosage of loop-diuretics is 
just a marker of more severe disease. Prospec-
tive trials are needed to further elucidate these 
findings, and it may be warranted to try to reduce 
the dosage of loop diuretics in the post-CRT 
implant phase. In cases, where the response to 
the treatment is poor and high dose diuretics are 
necessary, further interventions are desirable to 
prevent an unfavourable clinical outcome.
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